Ron Cohen
President & CEO
Acorda Therapeutics

Ron Cohen, M.D. is President, CEO and founder of Acorda Therapeutics, Inc., a public biotechnology company developing therapies for disorders of the nervous system, including multiple sclerosis, Parkinson’s disease and migraine. Dr. Cohen previously was a principal in the startup and an officer of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation uses. He serves as a Director on the Board of Directors of VBL Therapeutics. He previously served as a Director on the Board of Dyax Corp. until its acquisition in 2016. He also previously served as Chair of the Board of the Biotechnology Innovation Organization (BIO), as Chair of the Emerging Companies Section of the BIO Board, and as Director and Chair of the New York Biotechnology Association (NYBA). Dr. Cohen is a member the Columbia-Presbyterian Health Sciences Advisory Council and was awarded Columbia University’s Alumni Medal for Distinguished Service.

Acorda Therapeutics has been recognized as one of the Best Companies to Work for in New York State seven years in a row (2011-2017), among the Fortune 100 Best Medium-Size Workplaces the U.S. (2017), and among the Fortune 100 Best Workplaces for Women (2016-2017), Millennials (2017) and Baby Boomers (2017).

Dr. Cohen is a recipient of the NY CEO Lifetime Achievement Award and the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region. He was named Neuroinvestment’s CEO of the Year and is an inductee of the National Spinal Cord Injury Association’s “Spinal Cord Injury Hall of Fame.” Dr. Cohen received the Burke Award from Burke Rehabilitation Hospital for his contributions to helping people with disabilities gain independence. He has been recognized by the New York Biotechnology Association as the NYBA “The Cures Start Here” Business Leader of the Year, by the Westchester County Association as its Leadership Award recipient, by Life Science Leader Magazine as True L